Emerson Perin, MD
Interventional Cardiology · Houston, TXNPI 1790737633
Payments from drug & device makers
What this record shows
36 manufacturers reported payments, led by Astrazeneca AB at 51.4% of the total. Reporting peaked in 2022 at $6,725 and has fallen 91.0% since, to $608 in 2025.
Across 334 payments — averaging $43.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca AB$8K
- Novartis$1K
- Novo Nordisk$816
- Johnson & Johnson$743
- Boston Scientific$542
- Medtronic$504
- plus $3K from 30 others
Across 39 payments — averaging $3203.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$39K
- Shockwave Medical, Inc$25K
- Astrazeneca UK Limited$24K
- Abbott$23K
- Array Biopharma Inc$14K
- Merck$500
What the payments were for
- Consulting fees$7,50051%
- Food & beverage$7,09949%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca AB | 3 | $7,500 |
| Novartis | 58 | $1,103 |
| Novo Nordisk | 36 | $816 |
| Johnson & Johnson | 54 | $743 |
| Boston Scientific | 14 | $542 |
| Medtronic(2 entities) | 10 | $504 |
| Abbott | 10 | $388 |
| Kowa Pharmaceuticals America, Inc. | 23 | $368 |
| Amarin Pharma, Inc. | 12 | $317 |
| E.r. Squibb & Sons, L.L.C. | 16 | $280 |
| Pfizer | 16 | $241 |
| Amgen | 12 | $213 |
| Impulse Dynamics (USA) Inc. | 6 | $177 |
| Irhythm Technologies, Inc. | 11 | $174 |
| Esperion Therapeutics, Inc. | 9 | $150 |
| Penumbra, Inc. | 1 | $130 |
| Sanofi-aventis U.S. LLC | 8 | $129 |
| Lexicon Pharmaceuticals, Inc. | 4 | $94 |
| Cardiva Medical, Inc. | 2 | $88 |
| Heartflow, Inc. | 3 | $81 |
| Alnylam Pharmaceuticals Inc. | 3 | $80 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $71 |
| Endologix LLC | 2 | $69 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Vifor Pharma, Inc. | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Avinger Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $34 |
| Bayer | 2 | $32 |
| Lilly USA, LLC | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| ZOLL Circulation Inc | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $12 |
| Medicure Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,599 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 24 | $542,634 |
| EliquisApixaban | 246 | $301,752 |
| JardianceEmpagliflozin | 177 | $233,470 |
| EntrestoSacubitril/Valsartan | 134 | $190,769 |
| FarxigaDapagliflozin Propanediol | 133 | $164,307 |
| Repatha SureclickEvolocumab | 141 | $117,919 |
| VascepaIcosapent Ethyl | 102 | $85,282 |
| XareltoRivaroxaban | 86 | $68,808 |
| BrilintaTicagrelor | 68 | $58,659 |
| OzempicSemaglutide | 35 | $41,363 |
| MultaqDronedarone Hcl | 21 | $26,164 |
| Praluent PenAlirocumab | 28 | $25,342 |
| Icosapent Ethyl | 31 | $16,919 |
| Metoprolol Succinate | 485 | $8,786 |
| Ezetimibe | 266 | $8,515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $241 | $844,386270 claims |
| Boehringer IngelheimJardiance | $34 | $233,470177 claims |
| AstraZenecaFarxiga, Brilinta | $14 | $222,966201 claims |
| NovartisEntresto | $1,103 | $190,769134 claims |
| Johnson & JohnsonXarelto | $743 | $68,80886 claims |
| Novo NordiskOzempic | $816 | $41,36335 claims |
| Sanofi-aventis U.S. LLCMultaq | $129 | $26,16421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Michele SartoriHouston$266K
- Abhijeet DhobleHouston$161K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.